Sonoma Pharmaceuticals, INC 10-Q quarterly reports

Sonoma Pharmaceuticals, Inc. announced a 60% year-over-year revenue increase for the first quarter ended June 30, 2026, driven by strong international sales and improved gross profit margins.

Sonoma Pharmaceuticals reports increased revenue and reduced net loss for Q3 2026, but faces substantial doubt about its ability to continue as a going concern.

Sonoma Pharmaceuticals, Inc. reported significant revenue growth in its latest quarter, but faces substantial doubt about its ability to continue as a going concern due to ongoing losses and cash burn.

Sonoma Pharmaceuticals, Inc. reported increased revenue but a wider net loss and significant cash burn, raising substantial doubt about its ability to continue as a going concern.

Sonoma Pharmaceuticals reports increased revenue for Q3 2025 but acknowledges ongoing material weaknesses in internal control over financial reporting.

Sonoma Pharmaceuticals experienced revenue growth in the second quarter of fiscal year 2025, but continues to operate at a loss, with ongoing efforts to improve financial controls.

Sonoma Pharmaceuticals reported a net loss of $1.143 million for the quarter ended June 30, 2024, with revenue slightly down compared to the same period last year.

Sonoma Pharmaceuticals appoints Jerome Dvonch as Chief Financial Officer and John Dal Poggetto as Controller, while also reporting a net loss for the third quarter of fiscal year 2024.